Theratechnologies Company Profile (TSE:TH)

About Theratechnologies (TSE:TH)

Theratechnologies logoTheratechnologies Inc. is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition Company.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: TSE:TH
  • CUSIP: N/A
  • Web:
  • Market Cap: C$547.69 million
  • Outstanding Shares: 74,415,000
Average Prices:
  • 50 Day Moving Avg: C$7.77
  • 200 Day Moving Avg: C$5.74
  • 52 Week Range: C$2.35 - C$8.72
  • Trailing P/E Ratio: N/A
  • P/E Growth: -198.68
Sales & Book Value:
  • Annual Revenue: C$38.35 million
  • Price / Sales: 14.28
  • Book Value: C$0.61 per share
  • Price / Book: 12.07
  • EBIDTA: $737,999.00
  • Net Margins: -24.83%
  • Return on Equity: -26.95%
  • Return on Assets: -14.73%
  • Average Volume: 168,844 shs.
  • Short Ratio: 1.85
Frequently Asked Questions for Theratechnologies (TSE:TH)

What is Theratechnologies' stock symbol?

Theratechnologies trades on the Tornton Stock Exchange (TSX) under the ticker symbol "TH."

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc (TSE:TH) issued its earnings results on Tuesday, July, 14th. The company reported $0.01 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.03. The company earned $7.08 million during the quarter, compared to the consensus estimate of $6.45 million. Theratechnologies had a negative return on equity of 26.95% and a negative net margin of 24.83%. View Theratechnologies' Earnings History.

Where is Theratechnologies' stock going? Where will Theratechnologies' stock price be in 2017?

2 brokers have issued 12-month target prices for Theratechnologies' stock. Their predictions range from C$7.15 to C$9.50. On average, they anticipate Theratechnologies' share price to reach C$8.05 in the next twelve months. View Analyst Ratings for Theratechnologies.

Who are some of Theratechnologies' key competitors?

Who are Theratechnologies' key executives?

Theratechnologies' management team includes the folowing people:

  • Dawn Svoronos, Independent Chairman of the Board
  • Luc Tanguay, President, Chief Executive Officer, Director
  • Philippe Dubuc, Chief Financial Officer, Senior Vice President
  • Lyne Fortin, Senior Vice President, Chief Commercial Officer
  • Christian Marsolais Ph.D., Senior Vice President - Scientific Affairs and Alliances
  • Marie-Noel Colussi, Vice President - Finance
  • Jocelyn Lafond, Vice President - Legal Affairs, Corporate Secretary
  • Pierre Perazzelli, Vice President - Pharmaceutical Development
  • Dale Weil, Director
  • Gilles Cloutier Ph.D., Independent Director

How do I buy Theratechnologies stock?

Shares of Theratechnologies and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Theratechnologies' stock price today?

One share of Theratechnologies stock can currently be purchased for approximately C$7.36.

MarketBeat Community Rating for Theratechnologies (TSE TH)
Community Ranking:  1.6 out of 5 ()
Outperform Votes:  29 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  92
MarketBeat's community ratings are surveys of what our community members think about Theratechnologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Theratechnologies (TSE:TH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: C$8.05

Analysts' Ratings History for Theratechnologies (TSE:TH)
DateFirmActionRatingPrice TargetDetails
7/3/2017National Bank FinancialDowngradeOutperform Market Weight -> Sector Perform Market WeightView Rating Details
6/21/2017ScotiabankReiterated RatingOutperformC$9.50View Rating Details
5/5/2017Canaccord GenuityReiterated RatingSpeculative BuyC$7.50View Rating Details
7/6/2016MackieLower Price TargetC$5.30 -> C$4.40View Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Theratechnologies (TSE:TH)
Earnings by Quarter for Theratechnologies (TSE:TH)
Earnings History by Quarter for Theratechnologies (TSE TH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/14/2015Q2($0.02)$0.01$6.45 million$7.08 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Theratechnologies (TSE:TH)
Current Year EPS Consensus Estimate: $-0.17 EPS


Dividend History for Theratechnologies (TSE:TH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Theratechnologies (TSE:TH)
Insider Trades by Quarter for Theratechnologies (TSE:TH)
Insider Trades by Quarter for Theratechnologies (TSE:TH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/18/2017Christian MarsolaisInsiderBuy3,000C$7.12C$21,360.00
7/17/2017Philippe DubucInsiderBuy1,000C$8.00C$8,000.00
5/24/2017Philippe DubucInsiderBuy600C$6.42C$3,852.00
4/7/2017Philippe DubucInsiderBuy400C$5.89C$2,356.00
7/7/2016G�Rald A LacosteDirectorBuy4,000C$2.36C$9,440.00
4/8/2016Philippe DubucInsiderBuy3,300C$2.00C$6,600.00
4/7/2016Pierre PerazzelliDirectorSell7,700C$1.95C$15,015.00
4/6/2016Pierre PerazzelliDirectorSell6,500C$0.38C$2,470.00
4/5/2016Marie-No�L ColussiInsiderSell10,000C$2.04C$20,384.00
4/5/2016Pierre PerazzelliDirectorSell6,500C$2.05C$13,325.00
6/26/2015G�Rald A LacosteDirectorBuy10,000C$1.47C$14,700.00
5/22/2015Paul PommierDirectorBuy20,300C$1.40C$28,420.00
5/21/2015Paul PommierDirectorBuy25,000C$1.38C$34,500.00
5/5/2015Dawn SvoronosDirectorBuy5,000C$1.26C$6,300.00
5/1/2015Lyne FortinInsiderBuy9,900C$1.23C$12,177.00
4/30/2015Luc TanguayDirectorBuy4,100C$1.19C$4,879.00
(Data available from 1/1/2013 forward)


Headline Trends for Theratechnologies (TSE:TH)
Latest Headlines for Theratechnologies (TSE:TH)
DateHeadline logoThe Best Kept Secret Of The Marijuana Boom - July 20 at 8:32 AM logoToday's Research Reports on Theratechnologies Inc., VBI Vaccines Inc., Aralez Pharmaceuticals Inc. and Immunovaccine Inc. - July 20 at 8:32 AM logoChristian Marsolais Purchases 3,000 Shares of Theratechnologies Inc (TH) Stock - July 19 at 1:15 PM logoTheratechnologies to Announce Financial Results for the Second Quarter of 2017 - July 6 at 12:53 PM logoNational Bank Financial Downgrades Theratechnologies Inc (TSE:TH) to Sector Perform Market Weight - July 6 at 7:50 AM logoFDA Grants Priority Review to HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab - July 1 at 8:11 AM logoWall Street Analyst Gives This 180% Gainer Another 29% Upside: Time to Buy? - June 23 at 12:05 AM logoTheratechnologies Inc (TH) Stock Rating Reaffirmed by Scotiabank - June 21 at 1:20 PM logoHydrogenics at 52-Week High on New Contract - June 8 at 3:50 PM logoShareholders Elect New Board Member During Theratechnologies' Annual Meeting - May 16 at 11:58 AM logoAmaya Hits 52-Week High on News - May 12 at 3:41 PM logoCanaccord Genuity Reiterates C$7.50 Price Target for Theratechnologies Inc (TH) - May 5 at 3:44 PM logoFutures up Slightly with Jobs Reports on Horizon - May 5 at 9:02 AM logoTheratechnologies Inc (TH) Given a C$7.15 Price Target by National Bank Financial Analysts - May 4 at 4:38 PM logoTheratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab - May 3 at 11:26 PM logoTheratechnologies reports 1Q loss - Yahoo Finance - April 8 at 8:24 AM logoBRIEF-Theratechnologies Q1 loss per share C$0.03 - April 7 at 12:58 PM logoEdited Transcript of TH.TO earnings conference call or presentation 6-Apr-17 12:30pm GMT - April 7 at 12:58 PM logoTheratechnologies to Announce Financial Results for the First Quarter of 2017 - March 31 at 3:11 AM logoTheratechnologies Inc (TH) Scheduled to Post Quarterly Earnings on Wednesday - March 28 at 8:23 AM logoBRIEF-Theratechnologies buys commercial rights to Ibalizumab in European Union and 4 additional territories - March 6 at 12:13 PM logoTheratechnologies Strikes Deal, Hits 52-Week High - March 6 at 12:13 PM logoTheratechnologies Acquires Commercial Rights to Ibalizumab in the European Union and Four Additional Territories - March 6 at 12:13 PM logoTheratechnologies Holds Investment Community Meeting and Provides Updated Financial Guidance for Its Fiscal Year 2017 - March 1 at 9:32 AM logoTheratechnologies to Host Investment Community Webcast on March 1, 2017 - February 24 at 11:57 AM logoTheratechnologies Announces Comparative PK Data on the Intramuscular and Intravenous Administration of the Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab - February 16 at 8:01 PM logoTheratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting ... - PR Newswire (press release) - February 15 at 6:29 AM logoTheratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab - February 15 at 6:29 AM logoTheratechnologies Announces Financial Results for Fiscal Year 2016 - February 9 at 6:07 AM logoBRIEF-Theratechnologies-Abstract submitted by Taimed for 24-week study of Ibalizumab phase III - Reuters - January 18 at 12:20 AM logoTheratechnologies Inc.: Ibalizumab 24-Week Pivotal Phase III Study Results Accepted as a Late Breaker Will Be Presented at CROI 2017 - January 18 at 12:20 AM



Theratechnologies (TH) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff